knowledge -WSS

knowledge

author：leisure time 2025-09-30 18:16:15 - browse：73

Pfizer and Moderna aren’t the only vaccine money-makers. Much of the revenue and profits from Covid-19 vaccines are flowing behind the scenes, going to the contract manufacturers and clinical-trial organizers that turn the shots from lab-bench theory to mass-produced reality.

Both AstraZeneca and Johnson & Johnson publicly committed to not profiting off their products during the pandemic — though AstraZeneca has reserved the right to declare the pandemic over on July 1, even if the World Health Organization has not. Pfizer and Moderna made no such pledge, with Pfizer expected to make $15 billion in vaccine-related revenue this year, while Moderna is forecasting $18.4 billion in vaccine sales.

Contractors hired to test and manufacture these vaccines have enjoyed a share of the profits without the same level of public scrutiny.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： FDA approves Moderna’s RSV vaccine, its second licensed product

Wikipedia

WSS

Medicare inequities exacerbate Puerto Rico’s health disparities

ASCO Daily Recap: CAR

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

He's a Nobel laureate. Critics say he was misleading on Covid

R1 RCM gets $5.8 billion buyout offer from private equity firm

focus

knowledge

leisure time

Anesthesiologist group: stop taking Ozempic before surgery

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Guidelines to prevent youth baseball injuries need more muscle

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Continuity nursing helped my family in our darkest PICU moments

New documents shed light on MD Anderson Cancer Institute feud

Heart attack and stroke risk calculators need revising

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Cancer drug shortages should be causing more outrage

With competition flaring, obesity drug hits goal in liver disease study

explore

FDA approves Moderna’s RSV vaccine, its second licensed product

PBM reform efforts get punted in Congress

Alabama IVF ruling threatens families facing fatal genetic disease

Community Health Systems hospitals under DOJ investigation

Dario to buy mental health app maker Twill in cash and stock deal

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

entertainment

leisure time

Wikipedia

focus